Çàðåãèñòðèðîâàòüñÿ

Ïîõîæèå òåìû

  1. Àäåíîìà îêîëîóøíîé ñëþííîé æåëåçû
    îò Park â ðàçäåëå Ýíäîêðèíîëîã
    Îòâåòîâ: 8
    : 01.09.2004, 19:30
  2. Àäåíîìà îêîëîóøíîé ñëþííîé æåëåçû
    îò Tes â ðàçäåëå Îíêîëîãè÷åñêèå çàáîëåâàíèÿ, ðàê
    Îòâåòîâ: 3
    : 01.09.2004, 19:30
  3. Ó ìîåé ìàòóøêè áûë äèàãíîç "ðàê îêîëîóøíîé ñëþííîé æåëåçû". Ïîñëå êóðñà ðàä...
    îò êîíñòàíòèí â ðàçäåëå Îíêîëîãè÷åñêèå çàáîëåâàíèÿ, ðàê
    Îòâåòîâ: 1
    : 16.05.2004, 07:52
  4. Îòâåòîâ: 1
    : 02.05.2004, 06:25
  5. Ñìåøàííàÿ àäåíîìà ëåâîé ñëþííîé æåëåçû
    îò Yuriy â ðàçäåëå Îíêîëîãè÷åñêèå çàáîëåâàíèÿ, ðàê
    Îòâåòîâ: 3
    : 03.10.2003, 01:24
  1. Park
    #1
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Ãàëèíà Àôàíàñüåâíà, ÿ ñíîâà ê Âàì çà ïîìîùüþ. Íå çíàþ, ïðàâäà, ñìîæåòå ëè Âû ÷òî-òî ïîñîâåòîâàòü, âåäü ýòî íå ñîâñåì Âàø âîïðîñ, íî Âû âåäü âñå çíàåòå.

    Ó ìåíÿ îáíàðóæèëè àäåíîìó îêîëîóøíîé ñëþííîé æåëåçû 2õ2,6ñì.  ïîíåäåëüíèê ëîæóñü â êëèíèêó ×ËÕ (7 ýòàæ).

     ÷åòâåðã - îïåðàöèÿ. Ãîâîðÿò äîâîëüíî ñëîæíàÿ, ïîä îáùèì íàðêîçîì. Áîþñü óæàñíî.

    Äîêòîð ñêàçàë, ÷òî ïîñëå óäàëåíèÿ àäåíîìû, íóæíî îòëîæòü áåðåìåííîñòü íà ãîä, îáúÿñíèâ ýòî òåì, ÷òî ïðè áåðåìåííîñòè ïðîèñõîäèò ãîðìîíàëüíûé âçðûâ è ýòî ìîæåò ñïðîâîöèðîâàòü ðåöèäèâ îïóõîëè. Ïî÷åìó èìåííî íà ãîä, âåäü ïðè áåðåìåííîñòè äàæå ÷åðåç 10 ëåò âñå-ðàâíî áóäåò ýòîò ñàìûé "âçðûâ"? ×òî Âû äóìàåòå ïî ýòîìó âîïðîñó? Äëÿ ìåíÿ ýòî âàæíî, òàê êàê ÿ è òàê âûæèäàëà 1,5 ãîäà ïîñëå ïîòåðè ðåáåíêà.

    È ÷òî Âû âîîáùå äóìåòå ïî ïîâîäó ïóñêîâîãî ìîìåíòà äëÿ âîçíèêíîâåíèÿ ïîäîáíûõ îïóõîëåé? Î÷åíü èíòåðåñíî Âàøå ìíåíèå.

    Ñïàñèáî çàðàíåå çà îòâåò. Ñ óâàæåíèåì. Åâãåíèÿ.

  2. Dr. Vad
    #2
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Åâãåíèÿ!



    Ïîçâîëüòå âûñêàçàòü ñâîå ìíåíèå, ïîêà îæèäàåòå îòâåò îò Ãàëèíû Àôàíàñüåâíû.



    Ðåöèäèâ ïëåéîìîðôíîé àäåíîìû çàâèñèò ñêîðåå îò îáüåìà îïåðàöèè: òàê ïðè âûëóùèâàíèè àäåíîóçëà äîñòàòî÷íî âûñîê 20-45%, òîãäà êàê ïîñëå òîòàëüíîãî óäàëåíèÿ - âñåãî 1-5%. È õîòÿ åñòü ðàáîòû, îïèñûâàþùèå ðàçíóþ ýêñïðåññèþ ðåöåïòîðîâ ê ïîëîâûì ãîðìîíàì ìåæäó îïóõîëåâîé è íîðìàëüíîé òêàíÿìè, íî ïîêà íè áåðåìåííîñòü, íè äð. ãîðìîíàëüíûå "âçðûâû" íå áûëè çàìå÷åíû êàê ïðîâîöèðóþùèå ôàêòîðû:



    Glas AS, Hollema H, Nap RE, Plukker JT. Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. Cancer. 2002 Apr 15;94(8):2211-6.



    À âîò íåïîëíîå óäàëåíèå ïîõîæå ìîæåò ïîâëèÿòü íà ðèñê ðåöèäèâà:



    The extended multifocal distribution of tumor recurrences after insufficient resection of pleomorphic adenoma (most often after enucleation) can explain a high incidence of further recurrences. Therefore, a total parotidectomy including removal of surrounding fat tissue seems to be appropriate for the initial treatment of recurrent pleomorphic adenoma.



    Èç Stennert E, Wittekindt C, Klussmann JP, Arnold G, Guntinas-Lichius O. Recurrent pleomorphic adenoma of the parotid gland: a prospective histopathological and immunohistochemical study. Laryngoscope. 2004 Jan;114(1):158-63.

  3. Melnichenko
    #3
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Ïàðê, çíàþ ÿ äàëåêî íå âñå, è ïðåêðàñíî, ÷òî êîëëåãè ïîìîãàþò. Íó à ñ 7-ãî ýòàæà ïðè ñëó÷àå çàãëÿíèòå ê íàì íà 6-îé..

  4. Park
    #4
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìûé äîêòîð Vad, ñïàñèáî çà îòâåò. Ïðàâäà, ÿ íå íàñòîëüêî õîðîøî çíàþ àíãëèéñêèé, ÷òîáû ïîëíîñòüþ ïîíÿòü ñìûñë âòîðîé öèòàòû. Ïîÿñíèòå, ïîæàëóéñòà.

    Ìíå, êàê ÿ ïîíÿëà. áóäóò äåëàòü ñóáòîòàëüíóþ ðåçåêöèþ, à íå òîòàëüíóþ. Íåò ëè ó Âàñ èíôîðìàöèè î âåðîÿòíîñòè ðåöèäèâà ïðè òàêîì âèäå îïåðàöèè?

  5. Park
    #5
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Ãàëèíà Àôàíàñüåâíà! Ñïàñèáî çà ïðèãëàøåíèå. Áûëà áû ñ÷àñòëèâà ñ Âàìè ïîçíàêîìèòüñÿ. À íà ïðåäìåò ÷åãî ìû áóäåì îáùàòüñÿ?

    Ñ óâàæåíèåì, Åâãåíèÿ.

  6. VanushkoVE
    #6
    ×èòàòåëü Íåäóã.Ðó
    Ðåêîìåíäóþ îáðàòèòüñÿ ñ âîïðîñîì íà êîíñóëüòàòèâíûé Ðóñîíêîôîðóì â ðàçäåë "îïóõîëè ãîëîâû è øåè" (http://pacient.oncoforum.ru/viewforum.php?f=12) ê äîêòîðó Í.Â. Ïàíêèíîé.

  7. Dr. Vad
    #7
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Åâãåíèÿ!



    Îáüåì îïåðàöèè åùå è çàâèñèò îò ðàñïðîñòðàíåííîñòè îïóõîëè â æåëåçå: îáû÷íî ñóáòîòàëüíàÿ ðåçåêöèÿ òàêæå äàåò íå âûøå 5% ðåöèäèâîâ.

    Ñóòü ïîñëåäíåé ôðàçû: ïðè ÐÅÖÈÄÈÂÀÕ (à íå ïåðâè÷íîé ðåçåêöèè!) àäåíîìû òîòàëüíóþ ðåçåêöèþ, âêëþ÷àÿ îêðóæ. æèðîâ. òêàíü, ñëåäóåò ñ÷èòàòü íàèáîëåå ðàöèîíàëüíîé òàêòèêîé ëå÷åíèÿ.

  8. Park
    #8
    ×èòàòåëü Íåäóã.Ðó
    Ñïàñèáî, äîêòîð, Âû ìåíÿ íåìíîãî óñïîêîèëè, òàê êàê ìàíäðàæ æóòêèé. Ïîñëå òîãî, êàê ïðî÷ëà Âàø ïðåäûäóùèé îòâåò î òîì, ÷òî òîëüêî òîòàëüíîå óäàëåíèå äàåò ãàðàíòèþ îò ðåöèäèâà, îáðàòèëàñü ê õèðóðãó ñ ïðîñüáîé óäàëèòü âñþ æåëåçó. Îòâåò áûë, ÷òî ïðè ýòîì ïðîèñõîäèò îáåçîáðàæèâàíèå ëèöà è êðîìå òîãî ýòî íå ïîëîæåíî "ïî çàêîíó".

    Òî, ÷òî Âû íàïèñàëè òåïåðü íàìíîãî ðàäîñòíåå. Ýòî òîæå äîñòîâåðíûå äàííûå?

    Ïðàâäà, ñêàçàëè, ÷òî ïîñëåîïåðàöèîííûé ïàðåç ïðàêòè÷åñêè íåèçáåæåí, òàê êàê âî âðåìÿ îïåðàöèè ïðîèñõîäèò âûäåëåíèå íåðâà è íàðóøàåòñÿ ïèòàíèå + ïîñëåîïåðàöèîííûé îòåê îêðóæàþùèõ òêàíåé.

    Ñïàñèáî.

  9. Dr. Vad
    #9
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Ðark!



    Ïî äàííûì îäíîé êëèíèêè â Ãåðìàíèè, êîòîðàÿ íà ïðîòÿæåíèè 8 ëåò ÷àñòè÷íî èëè ïîëíîñòüþ óäàëÿëà æåëåçó âìåñòå ñ àäåíîìîé ïî ïàðåçàì ìîæåò áûòü ñëåäóþùàÿ ñòàòèñòèêà (170 ïàöèåíòîâ): ÷àñòè÷íûé âðåìåííûé ïàðåç - â 25% ñëó÷àåâ, ïîëíûé âðåìåííûé ïàðåç - 3%. ×àñòè÷íûé ïîñòîÿííûé ïàðåç 5%, ïîëíûé ïîñòîÿííûé - íèêîãäà.



    Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6.



    Pleomorphic adenoma of the parotid gland: a 13-year experience of consequent management by lateral or total parotidectomy.



    Guntinas-Lichius O, Kick C, Klussmann JP, Jungehuelsing M, Stennert E.

Êëèíèêà ñòîìàòîëîãèè è êîñìåòîëîãèè â Ìîñêâå

Ìåòêè ýòîé òåìû

Âàøè ïðàâà

  • Âû ìîæåòå ñîçäàâàòü íîâûå òåìû
  • Âû ìîæåòå îòâå÷àòü â òåìàõ
  • Âû íå ìîæåòå ïðèêðåïëÿòü âëîæåíèÿ
  • Âû íå ìîæåòå ðåäàêòèðîâàòü ñâîè ñîîáùåíèÿ
  •